do glp-1 agonists have cardiovascular benefit Glucagon-like peptide 1 receptor agonists: benefits and mechanisms of action GLP-1 receptor agonists and myocardial

Is retatrutide FDA-approved for weight loss

States which previously had coverage such as California, New Hampshire, Pennsylvania and South Carolina have also eliminated GLP-1 coverage for weight loss in recent months

Ozempic was (and still is) not FDA-approved for weight loss in patients without diabetes

A., Seluanov, A., Sierra, F., Verdin, E., & Lpez-Otn, C

The table below summarizes average weight loss outcomes and key clinical characteristics from major randomized controlled trials and real-world evidence

Benefits can include: Lower blood pressure Lower total cholesterol Better liver health for those with metabolic dysfunctionassociated steatotic liver disease (MASLD) Lower blood sugar and reduced diabetes risk Lower risk of kidney disease Tirzepatide and orforglipron are newer drugs that dont yet have results from long-term cardiovascular health trials